Full Press Release Details
Bio, Inc. to Report First Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, May 3
to host conference call and webcast at 4:30 pm ET on that day
Raton, Florida, April 24, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage
immunology company focused on developing treatments that harness a patient's innate immune system to fight disease, today
announced that it will host a conference call on Wednesday, May 3, 2023 at 4:30 PM Eastern Time to discuss results for its first quarter
ended March 31, 2023 and to provide a corporate update.
participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio First Quarter
Conference Call when reaching an operator.
Time: 4:30 PM Eastern Time
Participant Dial-in: 1-844-826-3035
Participant Dial-in (international): 1-412-317-5195
Conference ID: 10177985
live audio webcast of the call can be accessed using this link or by clicking here:
transcript will follow approximately 24 hours from the scheduled call. A replay will also be available through May 10 by dialing 1-844-512-2921
or 1-412-317-6671 (international) and entering PIN no. 10177985.
a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune
system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis
Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate
immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can
treat cancer (INB03 ), Early Alzheimer's disease, and treatment-resistant depression (XPro ). The Natural Killer Cell
Priming Platform includes INKmune developed to prime a patient's NK cells to eliminate minimal residual disease in patients
with cancer. INmune Bio's product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic
and solid tumor malignancies, and chronic inflammation. To learn more, please visit www.inmunebio.com.
trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press
release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements
contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing
of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these
risks and uncertainties. INB03 , XPro1595 (XPro ), and INKmune are still in clinical trials or preparing to start
clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any
assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that
could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties
relating to the Company's ability to produce more drug for clinical trials; the availability of substantial additional funding
for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization;
and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies.
These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission,
including the Company's Annual Report on Form 10-K, the Company's Quarterly Reports on Form 10-Q and the Company's
Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event
or circumstance that may arise after the date of this release.
David Moss, CFO (858) 964-3720
(516) 842-9614 x-823